AC Immune SA (ACIU) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
AC Immune SA (ACIU) has outperformed Cartesian Therapeutics (RNAC) over the past year, losing 17.6% versus a loss of 30.4%. Over five years, ACIU leads with a -60.4% price change compared with -94.7% for RNAC. AC Immune SA is the larger company by market cap ($237.6 million vs $189.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | RNAC |
|---|---|---|
| Share price | $2.39 | $6.27 |
| Market cap | $237.63M | $189.70M |
| 1-day change | -2.45% | -4.71% |
| YTD return | -23.89% | -13.04% |
| 1-year return | -17.59% | -30.41% |
| 5-year return | -60.36% | -94.71% |
| Forward P/E | 3.98 | — |
| EPS (TTM) | $-0.54 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.80M |
| Revenue growth (YoY) | — | -92.81% |
| Net income (latest FY) | — | $-130.30M |
| Operating margin | — | -5127.10% |
| Net margin | — | -4658.63% |
| 52-week high | $4.00 | $11.00 |
| 52-week low | $2.10 | $5.60 |
| Distance from 52-week high | -40.25% | -43.00% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +261.51% | +437.00% |
| Average volume | 198.18K | 131.23K |
| Shares outstanding | 99.43M | 30.26M |
| Employees | 90 | 75 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACIU has outperformed RNAC by 12.8 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Healthcare · Biotechnology · 90 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Healthcare · Biotechnology · 75 employees
ACIU vs RNAC FAQ
Which is bigger, AC Immune SA or Cartesian Therapeutics?
AC Immune SA (ACIU) is larger, with a market capitalization of $237.63M compared with $189.70M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, ACIU or RNAC?
ACIU returned -17.59% over the past 12 months, compared with -30.41% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.